Inhaled nitric oxide (iNO) has quickly become a standard therapy for term and near-term infants with hypoxic respiratory failure and persistent pulmonary hypertension. Its effect on the lung is believed to be through the stimulation of soluble guanylyl cyclase and the increased production of cyclic guanosine 3 0 ,5 0 -monophosphate (cGMP). However, in addition to pulmonary vasodilation and a decrease in pulmonary vascular resistance, nitric oxide (NO) shows several additional potential beneficial effects on the lung. This article reviews NO mechanisms of action, early clinical trial of iNO and clinical aspects for the use of iNO in acute respiratory failure of the term and near-tem neonates.
Introduction: nitric oxide Nitric oxide (NO) is a colorless, odorless gas. Earlier, NO was considered only as the toxic product of internal combustion engines, burning cigarettes and lightening storms. The atmospheric concentration of NO is 10 to 500 p.p.b. (parts per billion) in general, 1.5 p.p.m. (parts per million) in heavy traffic and 1000 p.p.m. in tobacco smoke. Human airways produce NO; within the nasal mucosa, NO concentrations reach 25 to 64 p.p.b. NO concentrations are considerably lower more distal, reaching 1 to 6 p.p.b. in the mouth, trachea and distal airways.
In spite of its Food and Drug Administration (FDA) approval in December 1999, NO continues to be confused with other compounds. Some are listed in Table 1 along with their chemical formula and bioactivity. The ability of NO to exist and exert biological activity in several states strengthens its position as a perfect second messenger (Table 2) .
Historical perspective
In 1980, Furchgott and Zawadzki 1 described how intact blood vessels, possessing intact endothelium and smooth muscle, dilated to stimuli that induced vasoconstriction when the endothelium was disturbed. He termed this substance, produced in vascular endothelial cells that relaxed blood vessels, endothelium-derived relaxing factor. Ignarro et al., 2 in 1987, help solve the riddle with compelling evidence supporting NO as the active signaling component of endothelium-derived relaxing factor. With Moncada's work in 1987, 3 also showing that NO is the active component of endothelium-derived relaxing factor, NO has also become appreciated as an important neurotransmitter. In 1996, by allowing NO gas to bubble through a tissue preparation containing guanylylcyclase, Ferid Murad 4 showed an increase in the production of cyclic guanosine 3 0 ,5 0 -monophosphate (cGMP), thus identifying the mechanism of action of this important molecule. For their pioneering work, Drs Furchgott, Ignarro and Murad received the 1998 Nobel Prize for Medicine.
Pulmonary vasodilatation: mechanism of action Nitric oxide activates soluble guanylyl cyclase, leading to the activation of cGMP-dependent protein kinase. In turn, cGMP-dependent protein kinase decreases the sensitivity of myosin to calcium-induced contraction and lowers the intracellular calcium concentration by activating calcium-sensitive potassium channels and inhibiting the release of calcium from the sarcoplasmic reticulum. The degradation of cGMP back to guanosine triphosphate is regulated under the control of a specific Nitroxyl anion NO type 5 phosphodiesterase. 5 Inhaled nitric oxide (iNO) is the first virtually selective pulmonary vasodilator in contrast to other medications. Tolazoline, nitroprusside or prostaglandins E 1 and D 2 , which also decrease pulmonary vascular resistance, but as nonselective vasodilating compounds, often has profound systemic effects (Figures 1 and 2) .
The biochemical fates of iNO at the alveolar-capillary membrane: small amounts of nitrogen dioxide (NO 2 ) may be formed if iNO mixes with high concentrations of oxygen (O 2 ) in the air space. Depending on the milieu of the lung parenchyma, NO may react with reactive oxygen species to form reactive nitrogen species such as peroxynitrite. In the vascular space, dissolved NO is scavenged by oxyhemoglobin (forming methemoglobin and nitrate) and, to a lesser extent, plasma proteins (for example, forming nitrosothiols, which are stable intravascular sources of NO activity). 5 The fate of intravascular NO is dose-dependent: Under normal conditions, NO produced by endothelial NO synthase with arginine as a substrate diffuses into smooth muscle to activate soluble guanylyl cyclase (sGC) to form cGMP and thus maintain basal vascular tone. Intravascular destruction of NO by intraerythrocytic hemoglobin is limited by diffusional barriers, including the red-cell-free layer adjacent to the endothelium and factors in and around the erythrocyte membrane that slow NO transit ( Figure 3 ). However, sufficient NO is consumed to limit the activity of NO to the local environment. When NO is administered by inhalation, high intravascular NO concentrations promote NO reactions, with erythrocyte hemoglobin and plasma proteins that can either protect it, thereby promoting systemic vasodilatation, or destroy it. During hemolysis or the infusion of hemoglobin-based blood substitutes, cell-free ferrous hemoglobin in the plasma rapidly destroys NO by being oxidized to methemoglobin and nitrate ions. Cell-free hemoglobin may diffuse into extravascular spaces. Limited NO bioavailability under these conditions promotes systemic vasoconstriction and organ dysfunctions. Figure 3 A model of the interactions of iNO (NO) with erythrocytes and cell-free hemoglobin in an arterial blood vessel. 6 The first human study with iNO was conducted in eight adults with pulmonary hypertension. 8 Pulmonary vascular resistance fell with iNO in all patients. This was not associated with a decrease in systemic vascular resistance, in contrast to treatment with intravenous prostacyclin.
Roberts et al. 9 and Kinsella et al. 10 described in 1992 the first use of iNO for the treatment of persistent pulmonary hypertension of the newborn (PPHN). Roberts treated six newborn infants with PPHN with up to 80 p.p.m. of iNO. In all six patients, preductal oxygen saturation increased; in five infants, postductal oxygen saturation and oxygen tensions also increased ( Figure 4 ). Inhalation of NO did not cause systemic hypotension.
Kinsella used a lower dose (10 to 20 p.p.m.) in nine newborn infants with PPHN. All showed a rapid improvement in oxygenation without a reduction in systemic blood pressure ( Figure 5 ). This study was the first to show the sustained effect of low-dose iNO in maintaining adequate oxygenation.
Larger randomized controlled studies examining different strategies of treatment with iNO in acute severe PPHN soon followed these pilot studies. The NINOS trial enrolled 235 term and near-term newborn infants with hypoxic respiratory failure, randomized to receive either iNO (20 p.p.m.) or a standard medical treatment (FiO 2 100%). Infants receiving iNO were significantly less likely to be treated with extracorporeal membrane oxygenation (ECMO).
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In another study, 12 Roberts randomized 58 newborn infants with PPHN to either iNO (80 p.p.m.) or placebo: in 53% of infants treated with iNO, oxygenation improved as compared with 7% in the control group. The use of ECMO was again significantly decreased in the iNO group (40 vs 71%). In the final randomized, controlled trial, which led to the FDA approval, Clark et al. studied a low-dose iNO therapy (20 p.p.m. in the first 24 h and then 5 p.p.m. for up to 4 days) in 248 infants who were randomized to iNO or placebo: ECMO treatment was again significantly lower in the iNO group (38 vs 64%). In addition, this was the first study to show in term infants a reduction in the risk for chronic lung disease (7 vs 20%). 13 Because ECMO was used as a rescue therapy, none of these studies showed a change in mortality.
Endogenously released and exogenously iNO may influence many facets of the developing perinatal lung, including the lung parenchyma, bronchi and vascular structures.
14 In a fetal or preterm lung during the transition from a saccular to an alveolar stage (25 to 28 weeks of gestation), endogenous NO is released primarily from epithelial and endothelial cells that contain NO synthase, and it is implicated in the structural and functional aspects of the development of pulmonary vasculature and airway smooth muscle. NO also contributes to growth of the lung parenchyma and to extracellular matrix deposition and may modulate surfactant and inflammation in the developing lung. The implications of supplementation with iNO in preterm infants are 15 beyond the scope of this review.
Potential beneficial effects of iNO
Thus, given the multiple mechanisms of action exerted by NO on the lung, its benefit may be mediated in several ways. Several are listed here:
(1) Improved V/Q matching: Hypoxic pulmonary vasoconstriction minimizes ventilation-perfusion mismatching in the presence of abnormal ventilation. iNO improves oxygenation by increasing blood flow to ventilated lung units. surfactant, improved the apparent ability of hydrophobic surfactant proteins to promote low-surface tension and improved lung volume by a process unrelated to surfactant function.
(4) Prevention of neomuscularization in patients with PPHN:
In a model of injured pup lungs, iNO protected against pulmonary remodeling induced by lung injury by mechanisms that are independent of pulmonary tone, inflammation or thrombosis.
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(5) Decreased reperfusion injury: A neonatal animal model of lung ischemia-reperfusion showed that iNO can prevent microvascular injury, endothelial dysfunction and pulmonary neutrophil accumulation.
(6) NO replacement: NO, produced by endothelial NO synthase, is critically involved in the cardiopulmonary transition from fetal to neonatal life. Endothelial NO synthase protein expression and mRNA were decreased by a half and two-thirds, respectively, in an animal model of pulmonary hypertension ( Figure 6 ).
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Clinical considerations Hypoxic respiratory failure of the term near-term infant: Hypoxemia of the near-term infant is caused by complex pathopysiological pathways that have a common end point of reduced perfusion of the lungs. In some patients, one of these mechanisms dominates but in others several mechanisms play along, contributing to the severe clinical picture.
Patent ductus arteriosus and/or patent foramen ovale with rightto-left extrapulmonary shunting. V/Q mismatching in the lungs: as in meconium aspiration syndrome. In some segments of the lungs, there is reduced ventilation and right-to-left intrapulmonary shunting, and other segments are hyperinflated, increasing the dead space. In a heterogeneous, patchy, a form of lung disease, iNO may improve the V/Q matching by dilating the vasculature bed around the ventilated segments. In a homogenous parenchymal lung disease, the response to iNO may be low: treatment of the underlying lung disease and better recruitment of the atelectatic lung may improve the response to iNO. Left ventricular dysfunction.
It is important to evaluate and treat each of these factors when treating the hypoxemic infants.
Echocardiography. Echocardiography is crucial in the evaluation and management of the hypoxemic (blue) baby. The study will measure evidence for PPHN: existence of patent ductus arteriosus and patent foramen ovale in the direction of the shunt, and the pressure at the right ventricle. PPHN can be also shown by the evidence of right-to left-extrapulmonary shunting, by a difference between the preductal and the postductal O 2 saturation. Currently, the best way to distinguish between a congenital heart lesion, which is dependent on right-to-left shunting (for example, interrupted aortic arch, total anomalous pulmonary venous return and hypoplastic left heart syndrome) in which treatment with iNO may not be indicated, other anatomical variations or a normal heart with maladaptation to the extrauterine circulation is with echocardiography. Echocardiography is also important to evaluate the cardiac performance and assess ventricular function.
Timing of treatment. Large-scale randomized studies support the efficacy of iNO in term and near-term infants (>34 weeks of gestation) in the first 2 weeks of life. 18 iNO has also been used post-ECMO. iNO has also been used in the treatment of late pulmonary hypertension complicating chronic lung disease with some reported success, 19, 20 although much of the data are anecdotal. The treatment of the premature infant is still under investigation and is beyond the scope of this review.
Indication for treatment.
Most of the studies that tested the efficacy of iNO in acute respiratory failure used enrolled infants with oxygenation index (OI) of 25 or above. 18 Most evidence supports the use of iNO to reduce the need for ECMO and/or death. Some studies that used less-stringent entry criteria showed improved oxygenation but did not reduce ECMO/death when compared with the more 'traditional' criteria. 21, 22 Dose. The first clinical trials used higher initial doses of 80 p.p.m. Subsequent studies changed the practice to an initial dose of 20 p.p.m. A review of the iNO treatment of 476 neonates revealed that starting at higher doses does not improve the major outcomes (ECMO and death), and there was no evidence that using higher dose leads to a more rapid improvement of the hypoxemia. Using higher does of iNO (>22 p.p.m.) led to an increase in methemoglobin levels. This may decrease the oxygencarrying capacity by hemoglobin. Using lower doses of iNO (<18 p.p.m.) achieved the same response of PaO 2 as the higher doses, and there were no differences in the adverse events.
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Risks and complications Methemoglobinemia. The incidence of methemoglobinemia has been low in clinical trials, occurring more commonly in neonates and with high inhaled doses, but usually is tolerated well.
Left ventricular dysfunction
Inhaled NO may have adverse hemodynamic effects in patients with significant preexisting left ventricular dysfunction. Studies with iNO in adults with preexisting, severe left ventricular dysfunction showed an increase in the left ventricular end-diastolic pressure. 24, 25 This increase in end-diastolic volume resulting from an iNO-induced increased pulmonary perfusion may not be tolerated by the poorly compliant left ventricle resulting in worsened, rather than improved, oxygenation.
Withdrawal. A randomized control study of iNO also examined the safety of its withdrawal in 155 term infants with pulmonary hypertension. For infants responding to the treatment, a dose-response relationship between the iNO dose and decrease in PaO 2 after discontinuing iNO was found (Figure 7) . A reduction in iNO to 1 p.p.m. before discontinuation of the drug seems to minimize the observed decrease in PaO 2 . For infants failing treatment, discontinuation of iNO could pose a life-threatening reduction in oxygenation (Figure 8 ). 26 A possible explanation for this phenomenon might be through an increase in the concentration of superoxide and peroxynitrite when treating with iNO. In an animal model, reactive oxygen species scavenging ameliorated alterations in endogenous NO signaling during iNO therapy (Figure 9 ). 27 Direct toxicity. At high inspired levels, NO is directly toxic to tissues and can cause methemoglobinemia, formation of NO 2 , pulmonary edema, alveolar hemorrhage and hypoxemia. At low inspired levels of iNO (20 p.p.m.) NO 2 formation is minimal. 28 Bleeding tendency. iNO is associated with increased bleeding time and inhibition of platelet aggregation in adults. 29, 30 A Cochrane review of randomized studies of iNO in the near-term infants did not find an association between the use of iNO and bleeding events. 18 
New information
The new clinical data emerging in the literature concentrate on the safety of iNO: A study in premature infants dropped the concerns that iNO might have a deleterious effect on surfactant proteins and function. This study showed a transient improvement of surfactant function after iNO treatment, 31 and that administration of iNO does not increase inflammatory markers in the alveolar fluid. 32 Neurodevelopmental outcome. Concerns raised regarding the long-term complications of long-term use of iNO. In a study that examined the effects of iNO in premature infants, the infants in the study group had improved neurodevelopmental outcomes at 2 years of age as compared with the placebo group. 33 A follow-up study at 18 to 24 months of age of the infants participating in the NINOS study showed that early iNO therapy (OI: 15 to 25) as compared with late therapy (OI>25) for respiratory failure in term and near-term infants was not associated with an increase in neurodevelopmental impairment or hearing loss. 21 This new data suggest that iNO might be beneficial for the developing brain.
Congenital diaphragmatic hernia. The pulmonary artery hypertension in congenital diaphragmatic hernia is, in part, secondary to underdevelopment and anatomical changes of the pulmonary vasculature (that is, maladaptation). In addition, left ventricular dysfunction and surfactant dysfunction may contribute to hypoxemia. These may lead to a different approach in treating the hypoxemic respiratory failure in these patients. Two studies that randomized infants with congenital diaphragmatic hernia to iNO or placebo 13, 34 failed to show improved outcome in terms of reduced use of ECMO or death.
Non-invasive low-dose iNO, delivered via nasal canula at the time of tracheal extubation, may benefit a subset of infants with congenital diaphragmatic hernia who cannot be weaned from iNO after surgical correction. 35 In this subset of patients, pulmonary vascular hyperactivity persisted in spite of parenchymal improvement. The role of iNO is likely far more complicated than simply vasodilation alone, as the NO/cGMP pathway is also involved in alveolar growth and lung angiogenesis. 36 Future directions and research consideration Unfortunately, not all infants with PPHN improve after the initiation of iNO therapy and refractory PPHN is common. Other pharmacologic modalities are important. On the basis of the regulation pathways that control the production of the NO-cGMP cascade, and other physiologic mechanisms that induce pulmonary vasoconstriction, the following pharmacological strategies might be useful in the prevention or amelioration of PPHN. Some of these have been studied in humans (adults or pediatric population) and some are still experimental, shown to be effective in animal studies.
cGMP-specific phosphodiesterase inhibitors (sildenafil)
The secondary messenger of NO, cGMP, is inactivated predominantly by PDE5 (phosphodiesterase type 5). Sildenafil, an inhibitor of PDE5, is a selective pulmonary vasodilator, partially because PDE5 is highly expressed in the lung. 5 Amelioration effects of iNO withdrawal. Rebound pulmonary hypertension caused by withdrawal of iNO can be markedly attenuated by increasing cGMP with sildenafil. 37 Therapy for pulmonary hypertension. A randomized placebo-controlled study in 278 adult patients with symptomatic pulmonary arterial hypertension, treatment with oral sildenafil showed an improvement in exercise capacity, WHO functional class and hemodynamics (Figure 10 ). 38 A model for meconium aspiration in piglets tested the efficacy of the intravenous form of sildenafil. Sildenafil completely reversed the increase in pulmonary vascular resistance, and was shown to Figure 10 Mean changes from baseline, with 95% confidence intervals, in the 6-min walking distance at week 12 in the placebo and sildenafil groups. 38 be a highly effective pulmonary vasodilator, which is at least as effective as iNO. 39 The effectiveness of the aerosolized form of sildenafil was tested in an animal model of PPHN. Sildenafil selectively decreased the pulmonary artery pressure. When Sildenafil was inhaled while simultaneously breathing NO, the pulmonary artery pressure decreased even further. 40 Human studies followed the animal studies for PPHN. Six patients with PPHN were randomized to enteral sildenafil and compared with seven patients who received placebo. Oral sildenafil improved OI in infants with severe PPHN, which suggests that oral sildenafil may be effective in the treatment of PPHN. 41 Soluble guanylate cyclase activators BAY 41-2272 is a novel direct activator of soluble guanylate cyclase. This compound was tested in an animal model for PPHN. The effectiveness of BAY 41-2272-induced pulmonary vasodilation increased during the development of pulmonary hypertension in a response that was greater than sildenafil. It also augmented the pulmonary vasodilation induced by iNO.
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PGI2 analogs
Iloprost is a stable analog of prostacyclin. Its mechanism of action is through a different signaling pathway, involving cAMP. The use of the inhaled formulation has been approved by the FDA for the use in adults. When given as the inhaled formulation, iloprost is a selective pulmonary vasodilator. A first study of the use of inhaled iloprost for children with pulmonary artery hypertension has been recently published, reporting sustained functional improvement in some children, although occasionally induced bronchoconstriction. 43 There are several anecdotal reports for the use of inhaled iloprost for refractory cases of PPHN, 44 most reporting improved oxygenation after the initiation of therapy. No adverse events were reported.
Endothelin-1 receptor antagonists (bosentan, sitaxsentan)
Endothelin-1 is a potent vasoconstrictor, and has been shown to participate in the regulation of the pulmonary vascular tone. 45 A Cochrane review of this class of drugs in conjunction with conventional therapy has shown that it can improve the clinical outcomes in adults with idiopathic pulmonary artery hypertension. 46 Almost no experience with ERAs exists in the neonatal population.
Rho-kinase inhibitors (fasudil, Y-27632)
Rho-kinase inactivates myosin light-chain phosphatase and promotes vasoconstriction. The inhalation of rho-kinase inhibitor in an animal model achieved pulmonary vasodilation. 47 
Superoxide dismutase
Hyperventilation and the formation of reactive oxygen species can inactivate iNO. In an animal model, intratracheal recombinant human superoxide dismutase, with or without iNO, increased oxygenation and reduced pulmonary vasoconstriction. 48 Expanding the pharmacologic options and the combination of several of these might improve the response to iNO and the clinical outcome of this devastating disease.
Summary
Since its discovery two decades ago, NO found its way to the arsenal of therapeutic approaches available to the neonatologist in the treatment of PPHN, a disease with high morbidity and mortality. Vast research, both in animal models and human, increased our understanding of the features of this gas and its benefits and downsides. iNO was found to be the first potent 'fairly' selective pulmonary vasodilator. NO has multiple mechanisms of actions that may benefit newborn infants with diseases associated with meconium aspiration and persistent pulmonary hypertension. Understanding the mechanism of action of iNO through the cGMP pathway led to the introduction of other medications in this pathway: in addition to increasing cGMP concentration through NO-induced stimulation, inhibiting cGMP metabolism through phosphodiesterase inhibition, by sildenafil, for example, may provide additional benefit. The combination of drugs affecting through this pathway and other pathways might have a synergistic effect, increasing the rate of success in the treatment of PPHN.
Disclosure
MD Schreiber has received lecture fees, consulting fees, and grant support from Ikaria. A Bin-Nun has declared no financial interests.
Duality of interest
Dr Schreiber has received grant support and honoraria from iNO Therapeutics/ IKARIA.
